+86-28-82633987sales@biopurify.com
cnen
  • iso9001 iso9001
  • iso17025 iso17025
  • usp usp
Alternate Text
Home > Literature List > Biodegradable Hypericin-Containing Nanoparticles for Necrosis Targeting and Fluorescence Imaging

Biodegradable Hypericin-Containing Nanoparticles for Necrosis Targeting and Fluorescence Imaging

Journal name:Mol. Pharmaceutics
Literature No.:
Literature Url: http://scholar.google.com/scholar_url?url=https://pubs.acs.org/doi/abs/10.1021/acs.molpharmaceut.9b01238&hl=zh-CN&sa=X&d=8747765301678285359&scisig=AAGBfm3bb40EFfdB2h_CFEynkS9FsES_Tw&nossl=1&oi=scholaralrt&hist=P1l9U8wAAAAJ:6061410958341296950:AAGBfm1SMj-qIFykR7xxSgbekTZuDQdibA
Date publication:March 26, 2020
Abstract[Abstract Image]Necrosis targeting and imaging has significant implications for evaluating tumor growth, therapeutic response, and delivery of therapeutics to perinecrotic tumor zones. Hypericin is a hydrophobic molecule with high necrosis affinity and fluorescence imaging properties. To date, the safe and effective delivery of hypericin to areas of necrosis in vivo remains a challenge because of its incompatible biophysical properties. To address this issue, we have developed a biodegradable nanoparticle (Hyp-NP) for delivery of hypericin to tumors for necrosis targeting and fluorescence imaging. The nanoparticle was developed using methoxy poly(ethylene glycol)-b-poly(ε-caprolactone) and hypericin by a modified solvent evaporation technique. The size of Hyp-NP was 19.0 ± 1.8 nm from cryo-TEM and 37.3 ± 0.7 nm from dynamic light-scattering analysis with a polydispersity index of 0.15 ± 0.01. The encapsulation efficiency of hypericin was 95.05% w/w by UV–vis absorption. After storage for 30 days, 91.4% hypericin was retained in Hyp-NP with nearly no change in hydrodynamic size, representing nanoparticle stability. In an ovarian cancer cell line, Hyp-NP demonstrated cellular internalization with intracellular cytoplasmic localization and preserved fluorescence and necrosis affinity. In a mouse subcutaneous tumor model, tumor accumulation was noted at 8 h postinjection, with near-complete clearance at 96 h postinjection. Hyp-NP was shown to be tightly localized within necrotic tumor zones. Histological analysis of harvested organs demonstrated no gross abnormalities, and in vitro, no hemolysis was observed. This proof-of-concept study demonstrates the potential clinical applications of Hyp-NP for necrosis targeting.

… Page 6. 6 EXPERIMENTAL SECTION Materials Hypericin with a purity of 98% was
purchased from Biopurify Phytochemicals Ltd. (Chendu, China). PEG-PCL (MW = 15000 Da, PDI = 1.15) was obtained from Advanced Polymer Materials Inc. (Montreal, Canada) … 
Related Products